Hot weather & blood pressure, heart

Medtronic Launches Next-gen Surgical Aortic Tissue Valve

Medtronic (NYSE: MDT) + today announced the launch of its next-generation Avalus Ultra surgical aortic tissue valve.

The medtech giant designed the valve to facilitate ease of use at implant and lifetime patient management. It offers clear visibility for future valve-in-valve procedures and straightforward sizing.

Other features of Avalus Ultra include a low profile and a polyetheretherketone (PEEK) base frame for consistent circularity. Medtronic said it has an industry-leading effective orifice area (EOA) that may allow for greater blood flow. It also features a radiopaque coil for clear visibility for future valve-in-valve procedures.

Avalus Ultra builds on 10 years of clinical experience and long-term durability from the original Avalus valve launched in 2017. The latest-generation valve picked up its own FDA clearance to treat aortic stenosis in January of this year. It offers an option for the surgical aortic valve replacement (SAVR) method of treating aortic valve disease.

Surgeons remove the native valve and insert the Medtronic artificial valve. Once in place, the device is sewn into the aorta and takes over the original valve's function to enable oxygen-rich blood flow out of the heart.

"Patients with aortic stenosis are experiencing more complex disease, and therefore, procedures need to evolve to optimize their surgical care," said Dr. Pieter Kappetein, VP and chief medical officer of the Cardiac Surgery, Structural Heart, and Mechanical Circulatory Support businesses in the Medtronic Cardiovascular portfolio. "Rooted in this evolving need, surgeons are demanding innovative technologies like the Avalus Ultra valve that is designed for increased ease of use and long-term durability to serve patients over their lifetime."

Medtronic Announces FDA Approval Of Newest-generation Evolut TAVR System For Treatment Of Symptomatic Severe Aortic Stenosis

The Evolut™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access

DUBLIN, March 27, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

The Medtronic Evolut™ FX+ TAVR system leverages market-leading valve performance with the addition of larger windows to facilitate coronary access.

The Evolut FX+ TAVR system offers larger coronary access windows through a modified diamond-shaped frame design, which is four times larger than previous iterations of the Evolut TAVR system. Evolut FX+ provides increased space for catheter maneuverability to facilitate access to coronary arteries of varying patient anatomies. Additionally, the new design does not compromise the market leading valve performance, excellent hemodynamics, and radial strength that clinicians expect from the Evolut platform.1

"We are committed to consistently developing and advancing minimally invasive solutions for physicians to treat their patients with aortic stenosis. This is reinforced by our continued innovation of the Evolut TAVR platform, which has delivered proven valve performance and durability to physicians and patients for years. The Evolut FX+ TAVR system was designed to facilitate coronary access across a diverse range of patient anatomies with no compromise to valve performance," said Jeffrey Popma, M.D., vice president and chief medical officer for the Coronary & Renal Denervation business and the Structural Heart & Aortic business, which are part of the Cardiovascular Portfolio at Medtronic.

Severe aortic stenosis occurs when the aortic valve leaflets become stiff and thickened and have difficulty opening and closing, making the heart work harder to pump blood to the rest of the body. Severe aortic stenosis often reduces a patient's quality of life and limits their daily activities. If left untreated, 50% of patients with symptomatic severe aortic stenosis can die from heart failure in as little as two years.2

The Evolut FX+ TAVR system is indicated for symptomatic severe aortic stenosis patients across all risk categories (extreme, high, intermediate, and low) in the U.S. Early Commercial Experience is planned for spring 2024 with full product launch anticipated in summer 2024.

About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more.

Story continues

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1Medtronic data on file compared to the Evolut platform. Bench top model may not be indicative of clinical performance.

2Ross J Jr, Braunwald E. Aortic stenosis. Circulation. July 1968; 38(1 Suppl):61-67.

Contacts:

Rachel Murray

Ryan Weispfenning

Public Relations

Investor Relations

+1-651-332-3286

+1-763-505-4626

(PRNewsfoto/Medtronic plc)

Cision

View original content to download multimedia:https://www.Prnewswire.Com/news-releases/medtronic-announces-fda-approval-of-newest-generation-evolut-tavr-system-for-treatment-of-symptomatic-severe-aortic-stenosis-302100338.Html

SOURCE Medtronic plc

Cision

View original content to download multimedia: http://www.Newswire.Ca/en/releases/archive/March2024/27/c3498.Html

View comments

Medtronic (NYSE: MDT)

Will Wearable Technology Make Us Healthier?

Medtronic, Fitbit, Apple, and other tech companies hope to combine wearable technology with data analytics to improve outcomes in important diseases such as diabetes.

Todd Campbell and Kristine HarjesMay 16, 2017

This Remarkable Device Revolutionizes Diabetes Treatment

The approval of Medtronic's artificial pancreas system ushers in a new era for type 1 diabetes treatment. Plus, a new study includes some surprising revelations regarding medical marijuana.

Todd Campbell and Kristine HarjesOct 12, 2016

---